Dr. Theresa Visarius, Immunophotonics Vice President Business Development and Managing Director of the Swiss subsidiary IPS Biopharma AG will be at the SACHS Associates 22nd Annual Biotech in Europe Forum for Global Partnering and Investment on Wednesday and Thursday, September 21st & 22nd.
Category: Latest News
Immunophotonics Announces Appointment of New Chief Medical Officer and Chief Scientific Officer
Immunophotonics, Inc. is thrilled to announce the addition of Dr. Edwina Baskin-Bey in the role of Chief Medical Office (CMO) and Dr. David Anderson in the role of Chief Scientific Officer (CSO). Dr. Baskin-Bey’s vast experience in leading global clinical development and regulatory strategy across multiple therapeutic areas will strengthen the clinical development program as...
Tomas Hode, Wei R. Chen, Siu Kit “Samuel” Lam T Cell Paper Publication
Immunophotonics would like to congratulate Ashley Hoover and Kaili Liu lead authors from the University of Oklahoma and to the co-authors Tomas Hode, Wei Chen, and Sui Kit “Samuel” Lam on the T-Cell Paper publication in Clinical and Translational Medicine July 2022 issue. Check out this pivotal publication on how immunological remodeling of T-cells can...
Society of Interventional Radiology Annual Scientific Meeting (SIR), June 11-16, 2022
Tomas Hode, PhD, Co-Founder, CIO, and President at Immunophotonics, Inc. will be attending the Society of Interventional Radiology Annual Scientific Meeting (SIR) in Boston, MA June 11 – 16, 2022.
Immunophotonics Announces First Patient Dosed in Phase 2a Clinical Trial of IP-001 in advanced solid tumor indications
Immunophotonics announced that the first patient has been dosed in the phase 2a portion of its Swiss clinical trial for treatment of multiple selected cancer indications. This multicenter clinical trial is designed to evaluate the immunologically mediated anticancer effects of intratumorally injecting the company’s lead asset, IP-001, following thermal ablation in patients with advanced solid...
Immunophotonics HEC-TV Interview
Immunophotonics was interviewed by HEC-TV, St. Louis on our lead asset IP-001. Immunophotonics would not be where they are today if it weren’t for the entire team, many of whom are featured in this segment. Great Job Abby Delawder, Chun Fung (Johnny) Wong, Siu Kit (Samuel) Lam, Lu Alleruzzo, Tomas Hode. To View Click Here
Swiss Biotech Day May 2-3, 2022
The Immunophotonics Team is thrilled to announce that Dr. Theresa Visarius of Immunophotonics Switzerland (IPS Biopharma) will be presenting at the Swiss Biotech Day on Tuesday, May 3rd in the Clinical Stage Development Company category.
US Oncology Research BioTech Day, Early Development Program Summit
Samuel Lam, PhD, Vice President of Science and Research at Immunophotonics, Inc. and Markus Joerger, MD, PhD, Clinical Trial Principal Investigator spoke at the US Oncology Research BioTech Day, Early Development Program (EDP) Summit in Coronado, California, on April 27, 2022 at 1:00 p.m. in the Glorietta Room. Immunophotonics thanks Dr. Dan Von Hoff and...
European Conference on Interventional Oncology (EICO 2022) April 24–27, 2022
Interested in learning how Immunophotonics, Inc. continues to explore the ability of IP-001 to transform a routine interventional-oncology procedure into a systemic immunotherapy against cancer. Tomas Hode, PhD, Co-Founder, CIO, and President at Immunophotonics, Inc. will be attending the European Conference on Interventional Oncology (EICO 2022) in Vienna, Austria April 24 – 27, 2022. This...
Immunophotonics Announces Appointment of Miguel Zubizarreta to Its Board of Directors
Immunophotonics has strengthened its leadership with the appointment of Miguel Zubizarreta to its Board of Directors. Mr. Zubizarreta, a tech pioneer and serial entrepreneur, joins a biotech-savvy slate of experts currently serving on the Board of Immunophotonics and brings a complementary set of proficiencies to the Board’s wealth of expertise within the pharmaceutical industry. Read...